loncastuximab tesirine

Drug Overview

Loncastuximab tesirine is a highly specialized cancer medicine. It acts as a Smart Drug and Targeted Therapy, meaning it is designed to seek out and destroy specific cancer cells while trying to limit damage to healthy cells in the body.

• Generic name: Loncastuximab tesirine
• US Brand names: Zynlonta
• Drug Class: Antibody drug conjugate, CD19-directed Targeted Therapy
• Route of Administration: Intravenous infusion (given through a needle directly into a vein)
• FDA Approval Status: Fully approved by the United States Food and Drug Administration.

What Is It and How Does It Work? (Mechanism of Action)

Loncastuximab tesirine is an antibody drug conjugate. You can think of this Targeted Therapy as a microscopic homing missile that carries a toxic payload directly to the tumor.

Here is how the drug works at the molecular level inside the body:

The medicine is made of two main parts joined together. The first part is a targeting antibody. The second part is a strong chemotherapy toxin called a pyrrolobenzodiazepine dimer.

Certain types of white blood cells, specifically B cells, have a special protein on their outer surface called the CD19 receptor. In B cell lymphomas, these cells grow out of control. When loncastuximab tesirine is infused into the blood, the antibody part acts like a magnet and binds perfectly to the CD19 receptor on the cancer cell.

Once attached, the cancer cell accidentally swallows the medicine, pulling it inside. Inside the cell, the bond holding the medicine together breaks apart. This releases the strong toxin directly into the cell. The toxin then travels into the cell’s command center, called the nucleus, and glues itself to the DNA. This creates a strong block, called a crosslink, that stops the DNA from unzipping. Because the cell can no longer read its DNA or divide, it triggers a natural self destruct signal and dies.

FDA-Approved Clinical Indications

Loncastuximab tesirine is approved to treat specific types of blood cancer when other treatments have stopped working.

Oncological uses:

• Relapsed or refractory large B cell lymphoma. This includes diffuse large B cell lymphoma, high grade B cell lymphoma, and primary mediastinal large B cell lymphoma. It is used in adult patients who have already received two or more different lines of treatment that did not work or stopped working.

Non oncological uses:

• None at this time.

Dosage and Administration Protocols

This medicine is given by a trained cancer care team in a clinic or hospital. The dose is calculated based on the patient’s body weight in kilograms.

Dose adjustments for organ problems:

No starting dose adjustments are needed for patients with mild to moderate kidney problems (renal insufficiency) or mild liver problems (hepatic insufficiency). However, doctors will monitor patients with severe liver problems very closely, as the drug may build up in the body and doses may need to be delayed or lowered.

Clinical Efficacy and Research Results

Recent clinical studies from 2020 to 2025, including the major LOTIS 2 trial, have shown strong results for loncastuximab tesirine in patients with difficult to treat lymphomas.

In these trials, the overall response rate was approximately 48 percent. This means that almost half of the patients saw their tumors shrink significantly. Even more importantly, about 24 percent of patients achieved a complete response, meaning all visible signs of the cancer disappeared from their scans.

For patients who responded to the medicine, the results lasted a median of over 10 months. The median overall survival for patients in the trial was about 9.9 months. These numbers are very encouraging for patients whose cancer has already resisted multiple other standard treatments.

Safety Profile and Side Effects

Because this is a strong Targeted Therapy, it can cause changes in the body that lead to side effects.

Common side effects (Occurring in greater than 10 percent of patients):

• Feeling very tired (fatigue)
• Fluid buildup and swelling in the arms, legs, or face (edema)
• Nausea
• Muscle and joint pain
• Skin rash, especially when exposed to sunlight
• Increased blood sugar levels
• Changes in liver enzymes (specifically gamma glutamyltransferase)

Serious adverse events:

• Severe fluid buildup: Fluid can collect in the lungs (pleural effusion) or around the heart (pericardial effusion), causing trouble breathing.
• Severe myelosuppression: A dangerous drop in white blood cells and blood platelets, which increases the risk of severe infections and bleeding.
• Severe skin reactions: Painful, blistering rashes that require medical attention.

Black Box Warning:

This medicine does not have a formal FDA Black Box Warning. However, prescribing guidelines carry strong warnings for doctors to watch for serious fluid retention, severe skin rashes, and low blood cell counts.

Management strategies:

To prevent fluid buildup and liver swelling, doctors require patients to take a steroid pill called dexamethasone starting the day before the infusion, the day of the infusion, and the day after. If a patient develops a severe rash or dangerously low blood counts, the doctor will pause the treatment until the body heals. For future cycles, the doctor may lower the dose or stop the medication completely.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

Research Areas:

Loncastuximab tesirine is deeply connected to the world of cellular immunotherapy. Because it targets the CD19 receptor, it shares a target with advanced regenerative treatments like CAR T cell therapy. Current research is heavily focused on how to sequence these treatments. For example, clinical trials are studying whether loncastuximab tesirine can be used to shrink tumors before a patient receives CAR T cell therapy, or if it can be used to treat patients whose cancer returned after receiving stem cell transplants or cellular immunotherapies.

Patient Management and Practical Recommendations

Patient safety is very important when taking this medicine. Both the care team and the patient must follow specific steps.

Pre-treatment tests to be performed:

• Complete blood count tests to ensure white blood cells and platelets are high enough for treatment.
• Liver function blood tests.
• A pregnancy test for women of childbearing age, as this drug can harm an unborn baby.

Precautions during treatment:

• Patients must avoid direct sunlight because the medicine makes the skin very sensitive and prone to severe rashes.
• Men and women must use effective birth control during treatment and for several months after the last dose.

Do’s and Don’ts list:

• Do take your prescribed dexamethasone steroid pills exactly as your doctor tells you before and after your infusion. This is critical to prevent swelling.
• Do tell your doctor immediately if you have trouble breathing, a new cough, or sudden weight gain, as these are signs of fluid buildup.
• Do wear a hat, long sleeves, and strong sunscreen if you must go outside during the day.
• Do report any signs of infection, like a fever or chills.
• Do not skip your blood test appointments between treatments.
• Do not get any live vaccines without talking to your oncologist first.
• Do not start any new over the counter medicines or herbal supplements without checking with your cancer care team.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and is not meant to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition, clinical trials, or treatment options. Do not disregard professional medical advice or delay seeking it because of something you have read in this material.